Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced ...

Since being sworn in as Health and Human Services (HHS) secretary, Robert F. Kennedy Jr has repeatedly tried to undermine public trust in vaccines. His agency recently took steps to slow down the ...

Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The news is the ...